Paxman Awarded Prestigious British American Business Award For Its US Success

In less than a year since gaining official clearance by the Food and Drug Administration; Paxman has installed or signed delivery agreements in the USA for 250 of its pioneering scalp cooling system at 121 cancer clinics.

Hair loss is consistently ranked as one of the most feared and a common side effects of chemotherapy treatment and often people will refuse it because they do not want to lose their hair. The damage that chemotherapy causes to the hair follicle can be alleviated by using the scalp cooling treatment, also known as the 'cold cap'. It works by reducing the temperature of the scalp by a few degrees immediately before, during and after the administration of chemotherapy.
In the UK, Paxman works directly with the NHS and private healthcare providers, including those who offer patients the opportunity to receive their chemotherapy treatment at home.

In the US, the family run company have developed a unique sales approach which involves pay-per-treatment and personal cap to ensure a more affordable scalp cooling option for patients. This approach has involved setting up a HQ in Houston, a call centre, pharmacy and logistics (collectively the Paxman Hub), technical services and employing US training specialists who support providers and patients throughout their scalp cooling journey from start to finish.

Paxman place scalp cooling systems on a low-cost lease with healthcare providers but directly bill the patient through the Paxman Hub for their scalp cooling cap and pay-per-use tokens. It is the only scalp cooler in the world to offer a single patient use cooling cap to each user.

CEO Richard Paxman, said: “It is a privilege to be presented with this prestigious award. The US market is the largest in the world, so we are incredibly proud of the progress we have had in our first year since receiving FDA clearance. Our success in the US market, which is key to our global expansion, is also testimony to the growing understanding of the importance of scalp cooling as a way of improving quality of life and giving patients increased control during chemotherapy treatment. I would also like to thank all the team in the US and UK, my family and partner for all their support enabling us to achieve this success.”

Currently the Paxman Scalp Cooling System has received market clearance for use during chemotherapy treatment for breast cancer. The company have also filed an application for use of its scalp cooling system during treatment of patients with solid tumours. The expanded FDA clearance will substantially increase the company’s accessible market in the US.

Paxman has already reached its initial target set for the US market – a total of 250 scalp cooling systems that are either installed or covered by signed delivery agreements – during the first year following FDA clearance.